Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Plant Advanced Technologies S.A. specializes in the biotechnological extraction of active compounds from plants, primarily focusing on the pharmaceutical and cosmetic industries. The company leverages its proprietary technology to enhance the yield and quality of plant-based extracts, positioning itself as a leader in sustainable sourcing in Europe.
Plant Advanced Technologies generates revenue primarily through the extraction of bioactive compounds from plants, which are sold to pharmaceutical and cosmetic companies. The company has a competitive advantage through its patented extraction technology that allows for higher yields and purity compared to traditional methods, enabling premium pricing.
Regulatory approvals for new plant-based compounds
Partnership agreements with major pharmaceutical firms
Technological advancements in extraction methods
Market demand for sustainable and natural ingredients
Regulatory changes impacting the approval of plant-based compounds
Technological disruption from competitors developing more efficient extraction methods
Emerging biotech firms with innovative extraction technologies
Large pharmaceutical companies developing in-house extraction capabilities
Negative cash flow impacting liquidity
Potential future capital needs for R&D and expansion
moderate - The company's performance is somewhat linked to consumer spending in the healthcare and cosmetics sectors, which can be cyclical.
Interest rates affect the company's cost of capital for financing R&D and operational expansion. Higher rates could dampen growth prospects.
minimal - The company has a manageable debt-to-equity ratio of 0.38, indicating limited reliance on credit.
growth - Investors interested in innovative biotechnology and sustainable solutions will find this company appealing.
high - The stock has shown significant price fluctuations, evidenced by a 1-year return of -28.4%.